At a glance
ClinicalIndex Comparison RecordPhase 3Not Yet Recruiting· 180 target
Drug / intervention
JYB1904 +1 moredrug
Likely dose
JYB1904 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1 Antihistamines
In Brief
A Phase 3 clinical trial evaluating JYB1904 and Placebo+JYB1904 for Chronic Spontaneous Urticaria. Not yet recruiting, targeting 180 participants.
Detailed Summary
This Phase III Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Spontaneous Urticaria
Countries--
Collaborators--
Timeline
Phase 3Not Yet Recruiting
202620272028
First PostedFeb 2026
Enrollment StartMar 2026
TodayJul 2026
Primary CompletionJun 2027
Study CompletionApr 2028
First PostedFeb 11, 2026
Enrollment StartMar 31, 2026
Primary CompletionJun 30, 2027
Study CompletionApr 28, 2028
TodayJul 1, 2026
Enrollment to primary: 1.2 yearsPosted 5 months agoPrimary completion in 12 months
Interventions
JYB1904drug
300 mg JYB1904 injection administered SC every 12 weeks (Q12W) from Day 1 to Week 48.
Placebo+JYB1904drug
Placebo administered SC on D1 and W12; 300 mg JYB1904 injection administered SC every 12 weeks (Q12W) from W24 to W48.